LINC01762: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

Target Name: LINC01762

NCBI ID: G101929023

LINC01762

Other Name(s): long intergenic non-protein coding RNA 1762 | Long intergenic non-protein coding RNA 1762, transcript variant 1

LINC01762: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

LINC01762 is a long non-coding RNA (lncRNA) that has been identified in various organisms, including humans. It has a unique feature that consists of 1,842 exons, 58 intron skipped, and 59 exons upstream of the start codon. LINC01762 is expressed in various cell types of the human body, including the brain, heart, liver, and muscle. The function and regulation of LINC01762 are still being studied to determine if it can be a potential drug target or biomarker.

Drug Target Potential

LINC01762 has been predicted to have various functions based on its gene expression profile. It is involved in the regulation of cell adhesion, migration, and the association with various diseases, including cancer. LINC01762 has also been shown to play a role in the regulation of neural development and plasticity. These functions make LINC01762 an attractive drug target for various therapeutic applications.

One of the reasons for LINC01762's potential as a drug target is its unique structure. Unlike most lncRNAs, LINC01762 has a perfect start codon, which is essential for protein synthesis. Additionally, the exon structure of LINC01762 allows for the production of a variety of isoforms, which can increase the potential for drug targeting by altering the localization and stability of the RNA.

Another potential mechanism by which LINC01762 can be targeted by drugs is its involvement in various signaling pathways. For example, LINC01762 has been shown to be involved in the regulation of T-cell development and in the development of neurodegenerative diseases. Additionally, LINC01762 has been shown to play a role in the regulation of cell cycle progression and apoptosis. These functions make LINC01762 a potential drug target for various therapeutic applications, including cancer and neurodegenerative diseases.

Biomarker Potential

LINC01762 has also been identified as a potential biomarker for various diseases. For example, LINC01762 has been shown to be expressed in various types of cancer, including breast, ovarian, and colorectal cancer. This suggests that LINC01762 may be a useful biomarker for the diagnosis and prognosis of cancer. Additionally, LINC01762 has been shown to be involved in the regulation of various signaling pathways, which may be relevant to the regulation of cancer growth and progression.

Conclusion

In conclusion, LINC01762 is a long non-coding RNA that has unique features, including its perfect start codon and the variety of exons. Its functions and regulation are still being studied, but its potential as a drug target and biomarker make it an attractive target for future research. Further studies are needed to determine the function and regulation of LINC01762, as well as its potential as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 1762

The "LINC01762 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01762 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets